When Will I See Results on Zepbound? Week-by-Week Timeline
In trials, 82% of adherent Zepbound users lost 5% or more of their body weight by week 12, and average loss at week 72 ranged from 15.0% on 5 mg to 20.9% on 15 mg. Here is how the timeline unfolds, and what a slow start really means.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
The first well-documented checkpoint for Zepbound (tirzepatide) is week 12: in a post hoc analysis of the SURMOUNT-1 trial, 82% of participants who took at least 75% of their assigned doses had lost 5% or more of their body weight by that point [3]. By week 72, average weight loss was -15.0% on 5 mg, -19.5% on 10 mg, and -20.9% on 15 mg, compared with -3.1% on placebo [1]. Weight loss then slows for most people, with a median time to plateau between roughly 24 and 36 weeks depending on starting BMI [4], and in the trial subgroup with obesity and prediabetes, continued treatment sustained most of the reduction out to three years [6].
One caution up front: every number on this page is a group average from clinical trials in which the drug was paired with a reduced-calorie diet and increased physical activity [1, 2]. Averages describe what happened to hundreds of people combined, not what any one person will lose in any given week. Individual results vary, and the trials themselves show that people who start slowly often catch up later [3].
What drug and trials do these numbers come from?
Zepbound is the brand name for tirzepatide. Tirzepatide is a 39-amino-acid synthetic peptide that acts on both GIP and GLP-1 receptors [1, 2]. It has a mean half-life of about 5 days, which supports once-weekly injection [2]. The FDA-approved indication is chronic weight management in adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease, always alongside a reduced-calorie diet and increased physical activity [2].
The main timeline data come from SURMOUNT-1, a phase 3 trial that assigned 2,539 adults with obesity or overweight plus a weight-related complication (diabetes excluded) in a 1:1:1:1 ratio to 5 mg, 10 mg, or 15 mg of tirzepatide or placebo for 72 weeks [1]. At baseline, participants had a mean weight of 104.8 kg, a mean BMI of 38.0, and 94.5% had a BMI of 30 or higher [1].
Why are the first 20 weeks a ramp-up period?
SURMOUNT-1’s 72 weeks included a 20-week dose-escalation period [1], and the trial had a prespecified key secondary endpoint measured at week 20 [2]. That means the early months of the trial were not full-dose treatment — participants were still working up to their target dose during the period when many people expect to see their fastest results.
What the trials do show is that the maximum tolerated dose in these studies was defined as 10 mg or 15 mg weekly [5].
What happens in the first weeks after starting?
The most common adverse events in SURMOUNT-1 were gastrointestinal, mostly mild to moderate, and they occurred primarily during dose escalation [1]. A 3-year analysis of the same trial found the same pattern: GI events clustered in the first 20 weeks during dose escalation [6]. Adverse events led to treatment discontinuation in 4.3% of the 5 mg group, 7.1% of the 10 mg group, 6.2% of the 15 mg group, and 2.6% of the placebo group [1].
No published figure in these sources breaks down average weight loss week by week during the first month, so there is no reliable “first four weeks” number to quote. The earliest well-documented checkpoint is week 12 [3].
How much weight loss is typical by week 12?
A post hoc analysis of SURMOUNT-1 looked at 1,545 tirzepatide-treated participants who took at least 75% of their assigned doses and had weights recorded at weeks 0, 12, 24, and 72 [3]. Of those, 1,267 (82%) had lost 5% or more of their body weight by week 12 — the “early responders” — while 278 (18%) had lost less than 5%, the “late responders” [3].
The late responders looked different at baseline: 45% were male versus 30% of early responders, and they had a higher mean weight (110.2 vs 103.6 kg), higher mean BMI (39.1 vs 37.7), and larger waist circumference (117.5 vs 113.4 cm) [3].
What if I’ve lost less than 5% at 12 weeks?
A slow start did not predict failure in the trial data. By week 24 — the end of dose titration — 194 of the 278 late responders (70%) had reached a 5% or greater weight reduction [3]. By week 72, 250 of the 278 (90%) had [3]. The mean time to reach a 5% reduction among late responders was 24.8 ± 12.7 weeks [3].
Higher tirzepatide doses were associated with higher proportions of participants hitting various weight-reduction thresholds at weeks 24 and 72 [3]. The analysis authors concluded that extending treatment well beyond 12 weeks may allow additional patients to achieve clinically meaningful weight reduction [3]. Whether to continue, pause, or change anything is a decision for the prescribing clinician — not something trial averages can answer for an individual.
When does weight loss slow down or plateau?
A separate post hoc analysis pooled 1,438 adherent SURMOUNT-1 participants and 259 SURMOUNT-4 participants who lost at least 5% of body weight by their trial’s primary endpoint (week 72 in SURMOUNT-1, week 88 in SURMOUNT-4) [4]. A plateau was defined as a weight change of less than 5% over a 12-week interval and over all subsequent 12-week intervals, measured from randomization [4].
In SURMOUNT-1, the median time to plateau by starting BMI category was 24.3 weeks for overweight, 26.0 weeks for class I obesity, and 36.1 weeks for both class II and class III obesity, with the class II and III times significantly longer than the overweight group (p<0.05) [4]. A later plateau was associated with the 10 mg and 15 mg doses, younger age, and female sex [4].
These medians describe when the typical participant’s loss flattened out — they are not deadlines, and they do not mean weight loss stops for everyone at that point. By week 72, 90.2%, 88.9%, 87.6%, and 87.8% of participants across the four BMI categories had reached a plateau [4]; the remaining participants had simply not yet met the plateau definition. Results in SURMOUNT-4 were similar [4].
How much weight loss happens by week 72?
At week 72 in SURMOUNT-1, mean weight change was -15.0% on 5 mg, -19.5% on 10 mg, and -20.9% on 15 mg, versus -3.1% on placebo (P<0.001 for all comparisons) [1]. The FDA’s statistical review reports the same 10 mg and 15 mg estimates (-19.5% with n=636 and -20.9% with n=630) and a placebo estimate of -3.1% (n=643) [2].
| Dose | Mean weight change at week 72 | Lost ≥5% | Lost ≥20% |
|---|---|---|---|
| 5 mg | -15.0% [1] | 85% [1] | not reported separately |
| 10 mg | -19.5% [1, 2] | 89% [1] | 50% [1] |
| 15 mg | -20.9% [1, 2] | 91% [1] | 57% [1] |
| Placebo | -3.1% [1, 2] | 35% [1] | 3% [1] |
The trial publication reported the ≥20% figure only for the 10 mg and 15 mg groups, not separately for 5 mg. The FDA review’s responder estimates for the 10 mg and 15 mg groups were 89.6% and 91.4%, versus 34.0% for placebo [2]. SURMOUNT-2, a separate trial in people with type 2 diabetes and obesity or overweight, reported its own week 72 results: -12.8% on 10 mg and -14.7% on 15 mg versus -3.2% on placebo, with 79.6% and 83.2% reaching 5% loss versus 32.0% on placebo [2].
What do the three-year results show?
The longest published data come from a 176-week (about 3.4-year) analysis that followed the 1,032 SURMOUNT-1 participants who had both obesity and prediabetes, treating them for 176 weeks followed by 17 weeks off treatment [6]. At week 176, mean weight change was -12.3% on 5 mg, -18.7% on 10 mg, and -19.7% on 15 mg, versus -1.3% on placebo (P<0.001) [6].
These figures do not show weight loss continuing to increase after year one. The week-176 means are slightly smaller in magnitude than the week-72 means, and they come from a different subgroup — participants with obesity plus prediabetes — so the two sets of numbers are not directly comparable. What the 176-week figures show is that most of the reduction was sustained over three years of continued treatment in that subgroup [6].
That analysis also found 1.3% of tirzepatide participants progressed to type 2 diabetes over 176 weeks versus 13.3% on placebo (hazard ratio 0.07, 95% CI 0.0 to 0.1); after the 17-week off-treatment period the figures were 2.4% versus 13.7% (hazard ratio 0.12, 95% CI 0.1 to 0.2) [6]. These diabetes-prevention results apply to the subgroup with prediabetes, not to everyone with obesity. No new safety signals were identified over the 3 years [6].
What happens if I stop taking Zepbound?
The trial evidence points to substantial regain. In SURMOUNT-4, 783 adults with obesity or overweight (excluding diabetes) enrolled in a 36-week open-label lead-in on the maximum tolerated dose (10 or 15 mg); the 670 who completed the lead-in and were randomized at week 36 had lost a mean of 20.9% [7]. Those 670 were then randomized 1:1 to continue tirzepatide or switch to placebo for 52 weeks [7]. From week 36 to week 88, the continued-treatment group lost another 5.5% on average while the group switched to placebo regained 14.0% — a difference of -19.4 percentage points (95% CI -21.2 to -17.7, P<0.001) [7].
At week 88, 89.5% of those who continued treatment had maintained at least 80% of their lead-in weight loss, versus 16.6% of those switched to placebo [7]. Counting from week 0, overall mean reduction was 25.3% with continued tirzepatide versus 9.9% after withdrawal [7]. Participants had a mean age of 48, 71% were women, and mean weight was 107.3 kg, across 70 sites in 4 countries [7].
Is lowering the dose an option instead of quitting?
SURMOUNT-MAINTAIN, a 112-week US trial, tested exactly that. After a 60-week open-label weight-loss period on the maximum tolerated dose (10 or 15 mg), 378 of 441 enrolled participants were randomized 3:3:2 to stay on the maximum tolerated dose (140), drop to 5 mg (144), or switch to placebo (94) for 52 more weeks [5].
At week 112, mean weight change from the start of the trial was -21.9% for those who stayed on the maximum tolerated dose, -16.6% for those who dropped to 5 mg, and -9.9% for placebo (p<0.0001 for all comparisons) [5]. Rescue tirzepatide — offered from week 84 to participants who regained more than 50% of lost weight — was needed by 11 of 138 (8%) in the maximum-dose group, 35 of 142 (25%) in the 5 mg group, and 60 of 90 (67%) in the placebo group [5]. In all, 345 of 378 participants (91%) completed the study [5]. The trial’s authors wrote that reducing to 5 mg might provide a valuable alternative to discontinuation, though individual responses vary [5]. Any dose change is a decision to make with a clinician.
How do trial timelines compare with real life?
Trial conditions were structured: every efficacy figure on this page comes from studies that combined tirzepatide with a reduced-calorie diet and increased physical activity [1, 2]. Not everyone in the trials finished, either — week 72 weight data were missing for 10.5% of the 10 mg group, 9.4% of the 15 mg group, and 21.6% of the placebo group in SURMOUNT-1 [2].
What this means is that trial averages — with diet and exercise support built in and dropouts imputed — may not match everyday experience for every person. No verified week-by-week average for people taking Zepbound outside of trials has been published in the sources here, so there is no reliable real-world timeline number to quote alongside the trial figures.
Quick week-by-week recap
| Timepoint | What the trials showed |
|---|---|
| Weeks 1–20 | Dose-escalation period; GI side effects mostly clustered here [1, 6] |
| Week 12 | 82% of adherent participants had lost ≥5% of body weight [3] |
| Week 24 | 70% of the 18% who started slow had reached ≥5% loss [3] |
| Weeks 24–36 | Median time to plateau, depending on starting BMI [4] |
| Week 72 | Averages -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% placebo; roughly 88–90% had plateaued [1, 4] |
| Week 176 | Sustained reduction in the prediabetes subgroup: -12.3% / -18.7% / -19.7% vs -1.3% placebo [6] |
| After stopping | +14.0% mean regain over 52 weeks off treatment in SURMOUNT-4 [7] |
Sources
- PubMed. Tirzepatide once weekly for the treatment of obesity.
- US Food and Drug Administration. Statistical review and evaluation, clinical studies: NDA 217806, tirzepatide.
- PubMed. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1.
- PubMed. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
- PubMed. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
- PubMed. Tirzepatide for obesity treatment and diabetes prevention.
- PubMed. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial.
- PubMed. Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.
- PubMed. Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.
Frequently asked questions
How fast does tirzepatide start working after the first injection?
Tirzepatide has a mean half-life of about 5 days and is dosed once weekly. No published source here gives a week-by-week weight figure for the first month. The earliest well-documented checkpoint is week 12, when 82% of adherent trial participants had lost 5% or more of body weight.
What counts as a normal amount of weight to lose in the first month?
The trial sources do not report a first-month average, so no reliable number exists to quote. The first clearly documented milestone is week 12, where 82% of adherent participants had lost at least 5% of body weight. All trial results also paired the drug with a reduced-calorie diet and increased physical activity [1, 2].
Is it a problem if I've lost less than 5% at 12 weeks?
Not necessarily. In the trial analysis, 18% of adherent participants were below 5% at week 12, but 70% of that group reached 5% loss by week 24 and 90% by week 72, with a mean time to 5% loss of 24.8 ± 12.7 weeks. The analysis authors concluded that continuing beyond 12 weeks may allow more patients to reach meaningful reduction.
Why did my weight loss stall, and when does the plateau usually hit?
In trial data, the median time to plateau ranged from 24.3 weeks in the lowest BMI category to 36.1 weeks in class II and III obesity. A later plateau was linked to 10 or 15 mg doses, younger age, and female sex. These are medians, not deadlines — by week 72, roughly 88–90% of participants had met the plateau definition.
How much is lost on 5 mg vs 10 mg vs 15 mg at 72 weeks?
In SURMOUNT-1, mean weight change at week 72 was -15.0% on 5 mg, -19.5% on 10 mg, and -20.9% on 15 mg, versus -3.1% on placebo. The FDA's statistical review reports the same 10 mg and 15 mg estimates.
Does weight loss keep going past one year?
The trials do not show loss continuing to increase after year one. A 176-week analysis of SURMOUNT-1 participants with obesity and prediabetes reported mean weight change of -12.3% on 5 mg, -18.7% on 10 mg, and -19.7% on 15 mg versus -1.3% on placebo — sustained reduction in that subgroup, not directly comparable with the week-72 whole-trial averages. No new safety signals emerged over 3 years.
Will I regain the weight if I stop?
In SURMOUNT-4, participants switched to placebo after 36 weeks regained a mean of 14.0% over the next 52 weeks, while those who continued lost another 5.5%. Overall reduction from week 0 to 88 was 25.3% with continued treatment versus 9.9% after withdrawal.
Is lowering the dose instead of quitting an option?
SURMOUNT-MAINTAIN tested this: after weight loss on a maximum tolerated dose, dropping to 5 mg produced -16.6% total weight change at week 112 versus -9.9% for placebo and -21.9% for staying on the maximum dose. The authors noted dose reduction might be an alternative to stopping, though responses vary. Any change belongs in a conversation with the prescribing clinician.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.